mRCC Patient Selection for Ipilimumab/Nivolumab
Daniel George, MD; Walter Stadler, MD; and Robert J. Amato, MD, consider which patients with metastatic renal cell carcinoma might benefit most from combination ipilimumab/nivolumab as a frontline or second-line therapy.
